Amarin Corp Plc\uk AMRN
Amarin Corp Plc\uk (Nasdaq: AMRN) is a cardio-renal-metabolic drug developer. Its lead program, VASCEPA (icosapent ethyl), is marketed for Severe hypertriglyceridemia (MARINE) and reduction of persistent cardiovascular risk in statin-treated high-risk patients (REDUCE-IT).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VASCEPA (icosapent ethyl) - US marketed; VAZKEPA in EU/UK via partners | Severe hypertriglyceridemia; cardiovascular risk reduction | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved cardio-renal-metabolic companies
- ELI LILLY & Co LLY
- Amgen Inc AMGN
- Scienture Holdings, Inc. SCNX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.